@article {7919,
	title = {Myeloma bone disease and proteasome inhibition therapies},
	journal = {Blood},
	volume = {110},
	year = {2007},
	note = {Cited By :89Export Date: 21 February 2017},
	month = {2007},
	pages = {1098 - 1104},
	abstract = {Bone disease is one of the most debilitating manifestations of multiple myeloma. A complex interdependence exists between myeloma bone disease and tumor growth, creating a vicious circle of extensive bone destruction and myeloma progression. Proteasome inhibitors have recently been shown to promote bone formation in vitro and in vivo. Preclinical studies have demonstrated that proteasome inhibitors, including bortezomib, which is the first-in-class such agent, stimulate osteoblast differentiation while inhibiting osteoclast formation and bone resorption. Clinical studies are confirming these observations. Bortezomib counteracts the abnormal balance of osteoclast regulators (receptor activator of nuclear factor-κB ligand and osteoprotegerin), leading to osteoclast inhibition and decreased bone destruction, as measured by a reduction in markers of bone resorption. In addition, bortezomib stimulates osteoblast function, possibly through the reduction of dickkopf-1, leading to increased bone formation, as indicated by the elevation in bone-specific alkaline phosphatase and osteocalcin. The effect of bortezomib on bone disease is thought to be direct and not only a consequence of the agent{\textquoteright}s antimyeloma properties, making it an attractive agent for further investigation, as it may combine potent antimyeloma activity with beneficial effects on bone. However, the clinical implication of these effects requires prospective studies with specific clinical end points. {\textcopyright} 2007 by The American Society of Hematology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548029349\&doi=10.1182\%2fblood-2007-03-067710\&partnerID=40\&md5=14feb7e5f8e2157c82ac8a848d92d050},
	author = {Terpos, E. and Sezer, O. and Croucher, P. and Dimopoulos, M.-A.}
}
